HRP20130986T1 - Aminopirazol triazolotiadiazol inhibitori c-met protein kinaze - Google Patents

Aminopirazol triazolotiadiazol inhibitori c-met protein kinaze Download PDF

Info

Publication number
HRP20130986T1
HRP20130986T1 HRP20130986AT HRP20130986T HRP20130986T1 HR P20130986 T1 HRP20130986 T1 HR P20130986T1 HR P20130986A T HRP20130986A T HR P20130986AT HR P20130986 T HRP20130986 T HR P20130986T HR P20130986 T1 HRP20130986 T1 HR P20130986T1
Authority
HR
Croatia
Prior art keywords
hydrogen
compound according
compound
methyl
fluoro
Prior art date
Application number
HRP20130986AT
Other languages
English (en)
Croatian (hr)
Inventor
David Lauffer
Pan Li
Kira Mcginty
Original Assignee
Vertex Pharmaceuticals Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42346870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20130986(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vertex Pharmaceuticals Incorporated filed Critical Vertex Pharmaceuticals Incorporated
Publication of HRP20130986T1 publication Critical patent/HRP20130986T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HRP20130986AT 2009-05-28 2010-05-27 Aminopirazol triazolotiadiazol inhibitori c-met protein kinaze HRP20130986T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18178609P 2009-05-28 2009-05-28
PCT/US2010/036312 WO2010138665A1 (en) 2009-05-28 2010-05-27 Aminopyrazole triazolothiadiazole inhibitors of c-met protien kinase

Publications (1)

Publication Number Publication Date
HRP20130986T1 true HRP20130986T1 (hr) 2013-11-22

Family

ID=42346870

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20130986AT HRP20130986T1 (hr) 2009-05-28 2010-05-27 Aminopirazol triazolotiadiazol inhibitori c-met protein kinaze

Country Status (25)

Country Link
EP (1) EP2435443B1 (enExample)
JP (1) JP5686796B2 (enExample)
KR (1) KR20120030110A (enExample)
CN (1) CN102459283B (enExample)
AR (1) AR076617A1 (enExample)
AU (1) AU2010254055B2 (enExample)
BR (1) BRPI1012037A2 (enExample)
CA (1) CA2762190A1 (enExample)
CL (1) CL2011002946A1 (enExample)
DK (1) DK2435443T3 (enExample)
ES (1) ES2433090T3 (enExample)
HR (1) HRP20130986T1 (enExample)
IL (1) IL216581A (enExample)
MX (1) MX2011012521A (enExample)
NZ (1) NZ596616A (enExample)
PL (1) PL2435443T3 (enExample)
PT (1) PT2435443E (enExample)
RS (1) RS53011B (enExample)
RU (1) RU2552993C2 (enExample)
SG (1) SG176574A1 (enExample)
SI (1) SI2435443T1 (enExample)
TW (1) TWI491614B (enExample)
UA (1) UA106082C2 (enExample)
WO (1) WO2010138665A1 (enExample)
ZA (1) ZA201108655B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2435444A1 (en) * 2009-05-28 2012-04-04 Vertex Pharmaceuticals Incorporated Substituted pyrazole inhibitors of c-met protein kinase
US8263777B2 (en) 2010-05-27 2012-09-11 Vertex Pharmaceuticals Incorporated Aminopyrazole triazolothiadiazole inhibitor of c-Met protein kinase
TR201113223A2 (tr) * 2011-12-29 2012-06-21 Koçak Farma İlaç Ve Ki̇mya Sanayi̇ A. Ş. Pemetrekset disodyum hazırlanmasına yönelik tek basamaklı işlem.
KR101373912B1 (ko) 2012-03-26 2014-03-13 중앙대학교 산학협력단 Ｓｈｐ－2의 활성을 특이적으로 저해하는 조성물 및 이의 제조방법
CN106924260B (zh) * 2015-12-31 2018-05-25 北京浦润奥生物科技有限责任公司 化合物在制备用于治疗脑胶质瘤的药物中的用途
CN109897054B (zh) * 2017-12-08 2021-12-10 中国药科大学 三唑并噻二唑类c-Met激酶抑制剂的制备方法及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5716981A (en) 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
CN1863780A (zh) * 2002-08-14 2006-11-15 沃泰克斯药物股份有限公司 蛋白激酶抑制剂及其应用
US7122548B2 (en) * 2003-07-02 2006-10-17 Sugen, Inc. Triazolotriazine compounds and uses thereof
JO2629B1 (en) * 2004-08-19 2012-06-24 افينتيس فارما سوتيكالز انك Branched carboxylic acid amides containing thienobirol, carboxylic acid amides containing pyrolithiazole, and the like as kinase inhibitors casein epsilon
CA2630884A1 (en) * 2005-11-30 2007-06-07 Vertex Pharmaceuticals Incorporated Inhibitors of c-met and uses thereof
ZA200804681B (en) * 2005-11-30 2009-11-25 Vertex Pharma Inc Inhibitors of C-Met and uses thereof
NL2000613C2 (nl) * 2006-05-11 2007-11-20 Pfizer Prod Inc Triazoolpyrazinederivaten.
KR101156845B1 (ko) * 2007-05-21 2012-06-18 에스지엑스 파마슈티컬스, 인코포레이티드 헤테로시클릭 키나제 조절제
CN102216309B (zh) * 2008-11-19 2014-05-07 沃泰克斯药物股份有限公司 C-met蛋白激酶的三唑并噻二唑抑制剂
EP2435444A1 (en) * 2009-05-28 2012-04-04 Vertex Pharmaceuticals Incorporated Substituted pyrazole inhibitors of c-met protein kinase

Also Published As

Publication number Publication date
CA2762190A1 (en) 2010-12-02
PT2435443E (pt) 2013-10-31
WO2010138665A1 (en) 2010-12-02
KR20120030110A (ko) 2012-03-27
AU2010254055B2 (en) 2016-01-14
PL2435443T3 (pl) 2014-01-31
ZA201108655B (en) 2013-01-30
RS53011B (sr) 2014-04-30
AR076617A1 (es) 2011-06-22
JP2012528186A (ja) 2012-11-12
SI2435443T1 (sl) 2013-12-31
CL2011002946A1 (es) 2012-07-27
NZ596616A (en) 2013-05-31
TW201100436A (en) 2011-01-01
RU2011153613A (ru) 2013-07-10
DK2435443T3 (da) 2013-10-28
CN102459283A (zh) 2012-05-16
AU2010254055A1 (en) 2011-12-15
BRPI1012037A2 (pt) 2016-05-17
SG176574A1 (en) 2012-01-30
TWI491614B (zh) 2015-07-11
ES2433090T3 (es) 2013-12-09
HK1169105A1 (en) 2013-01-18
IL216581A0 (en) 2012-02-29
EP2435443A1 (en) 2012-04-04
RU2552993C2 (ru) 2015-06-10
CN102459283B (zh) 2014-11-12
IL216581A (en) 2014-02-27
JP5686796B2 (ja) 2015-03-18
EP2435443B1 (en) 2013-07-31
MX2011012521A (es) 2012-01-30
UA106082C2 (uk) 2014-07-25

Similar Documents

Publication Publication Date Title
MX2016006919A (es) Nucleotidos para el tratamiento de cancer de higado.
HRP20131081T1 (hr) Kombinirane terapije koje sadrže hinoksalin inhibitor p13k-alfa za uporabu u lijeäśenju kancera
HRP20171957T1 (hr) Derivati 2-(2,4,5-supstituiranog-anilino) pirimidina kao modulatori egfr koji su korisni za liječenje raka
NZ626942A (en) New indolizine derivatives, method for preparing same and pharmaceutical compositions containing same
ME02663B (me) Derivati benzimidazola kao inhibitori pi3 kinaze
HRP20180538T1 (hr) Inhibitori za erk i postupci njihove uporabe
HRP20220255T1 (hr) Derivati 6,7,8,9-tetrahidro-3h-pirazolo[4,3-f]izokinolina koji su korisni u liječenju raka
HRP20171030T1 (hr) Modulatori enzima koji modificiraju metil, njihove smjese i uporaba
RU2015107552A (ru) Бивалентные ингибиторы ингибиторов белков апоптоза и терапевтические способы их применения
ME03804B (me) Karbamoiloksimetil triazol cikloheksilne kiseline kao antagonisti lpa
HRP20202073T1 (hr) Derivati n-(fenilsulfonil)benzamida kao bcl-2 inhibitori
HRP20151399T1 (hr) Kinazni inhibitor koji regulira signalni put apoptoze
HRP20161074T1 (hr) Benzoksazolski inhibitori kinaza i postupci njihove upotrebe
HRP20200561T1 (hr) Prolijekovi spoja jak inhibitora za liječenje gastrointestinalnih upalnih bolesti
RS56066B2 (sr) Supstituisani ksantini i postupci za njihovu upotrebu
JP2015529235A5 (enExample)
HRP20171999T1 (hr) Novi derivati aminopirimidina
HRP20220840T1 (hr) Inhibitori receptora faktora rasta fibroblasta
CL2014000395A1 (es) Compuestos derivados de piridazinona sustituida; compuesto intermediario; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de la esquizofrenia, trastorno esquizoafectivo, trastornos cognitivos o dolor.
ME02729B (me) Indolski i indazolski spojevi koji aktiviraju ampk
JP2013523710A5 (enExample)
HRP20120785T1 (hr) Spojevi i postupci za inhibiciju napredovanja mitoze putem inhibicije aurora kinaze
HRP20140705T1 (hr) Spoj triazolopiridina i njegovo djelovanje kao inhibitora prolil hidroksilaze i induktora proizvodnje eritropoetina
ME02423B (me) 1-(3,3-DIMETILBUTIL)-3-(2-FLUOR-4-METIL-5-(7-METIL-2-(METILAMINO)PIRIDO[2,3-d]PIRIMIDIN-6-IL)FENIL)UREA KAO INHIBITOR Raf KINAZE U LIJEČENJU RAKA
JO3336B1 (ar) مركبات أمينو بيريديلوكسي بيرازول